# An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

> **NCT05025332** · PHASE2 · COMPLETED · sponsor: **Neuren Pharmaceuticals Limited** · enrollment: 28 (actual)

## Conditions studied

- Pitt Hopkins Syndrome

## Interventions

- **DRUG:** NNZ-2591

## Key facts

- **NCT ID:** NCT05025332
- **Lead sponsor:** Neuren Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-14
- **Primary completion:** 2024-02-27
- **Final completion:** 2024-05-03
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025332, "An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05025332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*